2026 LCRF Award on Advancing Breakthroughs in ALK-Positive Lung Cancer

About this program

The Lung Cancer Research Foundation (LCRF) offers the 2026 Award on Advancing Breakthroughs in ALK-Positive Lung Cancer to support basic, translational, and developmental therapeutic research addressing ALK-driven disease, treatment resistance, and novel therapies. Awards provide up to $300,000 over two years, with at least two awards expected, and proposals should preferably be linked to an ongoing or planned clinical trial that includes correlative or translational research; early-phase dose-seeking trials are excluded. Applicants must be cancer researchers affiliated with nonprofit academic or research institutions, although industry collaborators may participate, and investigators from U.S. and international institutions are eligible regardless of citizenship. Applicants may not hold overlapping LCRF funding or apply to more than one LCRF funding track in the cycle; invited full proposals must include a patient or patient advocate on the research team.